Journal of Clinical Oncology, Vol 16, 204-209, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Radiation therapy for relapsed CNS germinoma after primary chemotherapy

TE Merchant, BJ Davis, JM Sheldon and SA Leibel
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. thomas.merchant@stjude.org

PURPOSE: To retrospectively evaluate the ability of radiation therapy to salvage patients with CNS germinoma who relapsed after treatment with primary chemotherapy on a multiinstitution trial that included carboplatin, etoposide, and bleomycin (PEB). PATIENTS AND METHODS: Eight patients with CNS germinoma received carboplatin, etoposide, and bleomycin as their only nonsurgical treatment following their initial diagnosis. At the time of relapse each patient received high-dose cyclophosphamide (one to three cycles) followed by craniospinal irradiation (25.2 to 36 Gy) and a boost to the site of recurrent disease (45 to 54 Gy). Six of eight patients had disease at relapse that was more extensive than at diagnosis. One patient had magnetic resonance imaging (MRI) evidence of leptomeningeal enhancement in the cauda equina although CSF cytology was negative, and one patient had cytologic evidence of CSF involvement. The median time to relapse following primary chemotherapy was 17 months. RESULTS: Although myelosuppression was prolonged following the administration of preirradiation chemotherapy, all patients completed a continuous course of radiation therapy. With a median follow-up after radiation therapy of 32 months (range, 16 to 47 months), no failures have occurred. CONCLUSION: Radiation therapy has a proven record of efficacy in the treatment of intracranial germinoma and it remains the standard therapy with which others are compared for treatment response, local control, and overall survival. Arguments can be made for alternative approaches when patients face hormonal or neurocognitive dysfunction as a result of radiation therapy; however, any reduction in late effects will have to be weighed against the probability of survival if alternative approaches prove to be inferior.

This article has been cited by other articles:

				S. Modak, S. Gardner, I. J. Dunkel, C. Balmaceda, M. K. Rosenblum, D. C. Miller, S. Halpern, and J. L. Finlay Thiotepa-Based High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Recurrent or Progressive CNS Germ Cell Tumors J. Clin. Oncol., May 15, 2004; 22(10): 1934 - 1943. [Abstract] [Full Text] [PDF]

				H. Aoyama, H. Shirato, J. Ikeda, K. Fujieda, K. Miyasaka, and Y. Sawamura Induction Chemotherapy Followed by Low-Dose Involved-Field Radiotherapy for Intracranial Germ Cell Tumors J. Clin. Oncol., February 1, 2002; 20(3): 857 - 865. [Abstract] [Full Text] [PDF]

				L. Horvath, D. McDowell, G. Stevens, R. Parkinson, S. McCarthy, and M. Boyer Unusual Presentations of Germ Cell Tumors: Case 2. Seminoma of the Conus Medullaris J. Clin. Oncol., February 1, 2001; 19(3): 911 - 915. [Full Text]

				Y. Shibamoto, K. Sasai, N. Oya, and M. Hiraoka Intracranial Germinoma: Radiation Therapy with Tumor Volume-based Dose Selection Radiology, February 1, 2001; 218(2): 452 - 456. [Abstract] [Full Text]

				M. Bamberg, R.-D. Kortmann, G. Calaminus, G. Becker, C. Meisner, D. Harms, and U. Gobel Radiation Therapy for Intracranial Germinoma: Results of the German Cooperative Prospective Trials MAKEI 83/86/89 J. Clin. Oncol., August 1, 1999; 17(8): 2585 - 2585. [Abstract] [Full Text] [PDF]